Drugs · acquisition-cost intelligence
OXYTROL
Oxybutynin· ingredient oxybutyninDrugs for urinary frequency and incontinence· OXYBUTYNIN 3.9 mg/d
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$2.73
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-11-192026-05-20
Same-ingredient options by acquisition cost
Other oxybutynin products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Oxybutynin Chloride | $0.03183 | −$2.70 |
| oxybutynin chloride | $0.04805 | −$2.68 |
| Oxybutynin Chloride Extended Release | $0.08961 | −$2.64 |
| Oxybutynin Chloride Extended Release | $0.10309 | −$2.63 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.